Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15580366 | 0.91 | HTR3A (0.37) | HTR3ALMNAKMT2AMEN1ABCC4 | |
| Vosaroxin SCHEMBL674441 | 0.89 | HTR3A (0.35) | HTR3ALMNAKMT2AMEN1ABCC4 | |
| Vosaroxin SCHEMBL15933161 | 0.89 | HTR3A (0.35) | HTR3ALMNAKMT2AMEN1ABCC4 | |
| Vosaroxin SCHEMBL195037 | 0.89 | HTR3A (0.35) | HTR3ALMNAKMT2AMEN1ABCC4 | |
| Vosaroxin SCHEMBL3207291 | 0.89 | HTR3A (0.35) | HTR3ALMNAKMT2AMEN1ABCC4 | |
| SCHEMBL12055755 | 0.89 | HTR3A (0.35) | HTR3ALMNAKMT2AMEN1ABCC4 | |
| SCHEMBL13212356 | 0.88 | CHRNA7 (0.34) | HTR3AKMT2AMEN1CHRNA7ALDH1A1 | |
| Vosaroxin SCHEMBL7824841 | 0.88 | HTR3A (0.35) | HTR3ALMNAKMT2AMEN1ABCC4 | |
| Hydrochloric Acid SCHEMBL7835838 | 0.88 | HTR3A (0.38) | HTR3ALMNAKMT2AMEN1ABCC4 | |
| Vosaroxin SCHEMBL7824869 | 0.88 | HTR3A (0.35) | HTR3ALMNAKMT2AMEN1ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | claimed |
| EP-3287126-A1 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY | Sunesis Pharmaceuticals, Inc. (US) | 2018-02-28 | — | — | EP | disclosed |
| EP-3284745-A1 | COMPOSITION OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | Sunesis Pharmaceuticals, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3284745-A1 | COMPOSITION OF (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | Sunesis Pharmaceuticals, Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| US-9839630-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839630-B2 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-12-12 | — | — | US | disclosed |
| EP-2382214-B1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| EP-2382214-B1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3-METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICALS INC (US) | 2017-07-19 | — | — | EP | disclosed |
| US-20170182015-A1 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY | SUNESIS PHARMACEUTICALS INC (US) | 2017-06-29 | — | — | US | disclosed |
| US-9676774-B2 | Compounds and compositions for treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20120148564-A1 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY | SUNESIS PHARMACEUTICALS, INC. | 2012-06-14 | — | — | US | disclosed |
| US-8124773-B2 | 1,8-naphthyridine compounds for the treatment of cancer | SUNESIS PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2382214-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-Ý(3S,4S)-3METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL¨-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | Sunesis Pharmaceuticals, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2354138-A1 | Compounds and compositions for treatment of cancer | Sunesis Pharmaceuticals, Inc. (US) | 2011-08-10 | — | — | EP | disclosed |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | SUNESIS PHARMACEUTICALS, INC. | 2010-08-12 | — | — | US | disclosed |
| WO-2010078294-A1 | METHOD OF PREPARING (+)-1,4-DIHYDRO-7-[(3S,4S)-3METHOXY-4-(METHYLAMINO)-1-PYRROLIDINYL]-4-OXO-1-(2-THIAZOLYL)-1,8-NAPHTHYRIDINE-3-CARBOXYLIC ACID | SUNESIS PHARMACEUTICAL, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| EP-2043645-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | Sunesis Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007146335-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| WO-2007146335-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | SUNESIS PHARMACEUTICALS, INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182015-A1 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY | BRCA1, MRE11, RAD51 | HTR3A 668/4885LMNA 964/4885KMT2A 2551/4885 |
| US-20100203162-A1 | Method of preparing (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid | CYP7A1, MT-ND1, DNM1 | HTR3A 513/4885LMNA 961/4885KMT2A 2993/4885 |
| US-20120148564-A1 | METHODS OF USING SNS-595 FOR TREATMENT OF CANCER SUBJECTS WITH REDUCED BRCA2 ACTIVITY | BRCA1, MRE11, RAD51 | HTR3A 668/4885LMNA 964/4885KMT2A 2551/4885 |
| US-20100029708-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF CANCER | NTPCR, NNMT, NES | HTR3A 2134/4885LMNA 546/4885KMT2A 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.